Valuation: Assertio Holdings

Market Cap 152M 132M 125M 114M 213M 14.57B 214M 1.5B 578M 7.41B 570M 558M 23.84B P/E 2024
-3.79x
P/E 2025 -1.91x
Enterprise Value 129M 112M 106M 96.23M 180M 12.35B 181M 1.27B 490M 6.28B 483M 473M 20.2B EV / Sales 2024
0.19x
EV / Sales 2025 0.3x
Free-Float
99.05%
Yield 2024 *
-
Yield 2025 -
1 day+0.09%
6 months+71.28%
Current year+159.10%
Current year 9.11
Extreme 9.11
23.5
1 year 8.61
Extreme 8.61
23.5
3 years 7.71
Extreme 7.705496
40.5
5 years 7.71
Extreme 7.705496
120.15
10 years 7.71
Extreme 7.705496
1,621.19
Director TitleAgeSince
Director/Board Member 26 16/06/2026
Director/Board Member - 16/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
13/5/26 Don

Chairman

-13,332 0.2069%
5/5/26 Free

Chairman

4,851 0.0753%
5/5/26 Free

Director

4,851 0.0753%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%-.--%+73.25%-40.88% 152M
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +0.04%+2.96%+30.05%+36.73% 360.19B
Weighted average by Cap. -0.04%+3.09%+34.85%+61.60%

Financials

2024 2025
Net sales 125M 109M 103M 93.43M 175M 11.99B 176M 1.23B 476M 6.1B 469M 459M 19.62B 119M 104M 97.74M 88.76M 166M 11.39B 167M 1.17B 452M 5.79B 446M 436M 18.63B
Net income -21.58M -18.82M -17.77M -16.14M -30.23M -2.07B -30.36M -213M -82.14M -1.05B -81.07M -79.27M -3.39B -30.38M -26.49M -25.01M -22.71M -42.55M -2.91B -42.73M -300M -116M -1.48B -114M -112M -4.77B
Net Debt -59.79M -52.14M -49.23M -44.7M -83.75M -5.74B -84.1M -590M -228M -2.92B -225M -220M -9.38B -23.15M -20.19M -19.06M -17.31M -32.43M -2.22B -32.57M -228M -88.12M -1.13B -86.97M -85.04M -3.63B
Logo Assertio Holdings
Assertio Holdings Inc is a United States-based commercial pharmaceutical company. The Company focused on the marketing and distribution of branded prescription medicines across several therapeutic categories. It maintains a portfolio that includes treatments for neurology disorders, inflammatory conditions, pain management, and oncology. Its activities involve acquiring, licensing, and integrating approved pharmaceutical products, followed by commercialization within the healthcare market. Its operating approach centers on identifying products that have established regulatory clearance and advancing their reach through targeted sales, medical education, and market access efforts. It manages product lifecycles through activities such as labeling updates, supply coordination, and engagement with healthcare professionals and payers.
Employees
53
  1. Stock Market
  2. Stocks
  3. ASRT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!